

Meeting Summary

Alabama Medicaid Agency Pharmacy and Therapeutics (P&T) Committee

November 3, 2021

Members Present: Dr. Lee Carter, Dr. Frances Heinze, Dr. Albert Holloway, Dr. Peter Hughes, Dr. Tiffany Lyght, Dr. Charles Nevels, Dr. Kelli Littlejohn Newman, and Dr. Christopher Stanley

Members Absent: None

Presenters: Dr. Eliza Anderson, Dr. Rachel Bacon, and Dr. Thomas Pomfret

Chairperson Carter called the Pharmacy and Therapeutics (P&T) Committee Meeting to order at 1:05 p.m. The minutes from the May 5, 2021 P&T Committee Meeting were approved with no corrections.

Pharmacy Program Update:

Dr. Newman stated that the federal COVID-19 state of emergency has been extended and the end date may continue to change. There have been updates to eyeglass and eye exam benefits for adults and the ambulance reimbursement rate increase has occurred. These updates are available on the website as ALERTs.

Pharmacotherapy Class Re-reviews (Please refer to the website for full text reviews.)

The pharmacotherapy class reviews began at approximately 1:08 p.m. There were 18 drug class re-reviews from the canceled August meeting. The Allylamines, Azoles, Echinocandins, Polyenes, Pyrimidines, Miscellaneous Antifungals, Antituberculosis Agents, Miscellaneous Antimycobacterials, Adamantanes, Interferons, Neuraminidase Inhibitors, Nucleosides and Nucleotides, Miscellaneous Antivirals, Amebicides, Antimalarials, Miscellaneous Antiprotozoals, and Urinary Anti-infectives were all last reviewed in May 2019. There were additionally 19 drug class re-reviews. The first generation antihistamines; estrogens; alpha glucosidase inhibitors; amylinomimetics; biguanides; dipeptidyl peptidase-4 inhibitors; incretin mimetics; insulins; meglitinides; sodium-glucose cotransport 1 inhibitors; sodium-glucose cotransport 2 inhibitors; sulfonyleureas; thiazolidinediones; antidiabetic agents, miscellaneous; prenatal vitamins; immunomodulatory agents used to treat multiple sclerosis; and antigout agents were all last reviewed in August 2019. The genitourinary smooth muscle relaxants: antimuscarinics and genitourinary smooth muscle relaxants: beta-3 agonists were last reviewed in November 2020.

The next P&T Committee Meeting is scheduled for February 9, 2022 at the Medicaid Building in the Commissioner's Board Room. There being no further business, Dr. Nevels moved to adjourn and Dr. Hughes seconded. The meeting adjourned at 2:56 p.m.